Nurix Therapeutics Announces Upcoming Presentation of NX-5948 Preclinical Data at the EULAR 2021 Virtual Congress
May 21, 2021 07:00 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, May 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical...
Arvinas to Present at the UBS Global Healthcare Virtual Conference
May 20, 2021 16:30 ET
|
Arvinas Inc.
NEW HAVEN, Conn., May 20, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Nurix Therapeutics to Participate in Upcoming Investor Conferences
May 11, 2021 07:00 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, May 11, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that members of...
Arvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven
May 04, 2021 14:52 ET
|
Arvinas Inc.
NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 04, 2021 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today...
Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
April 13, 2021 16:01 ET
|
Nurix Therapeutics, Inc.
On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021 Expanded Sanofi collaboration resulting in option exercise payment of $22 million Strong financial position after...
Nurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
April 07, 2021 07:00 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T....
Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
April 05, 2021 16:30 ET
|
Arvinas Inc.
NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers
March 16, 2021 09:31 ET
|
Nurix Therapeutics, Inc.
Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and medulloblastomaProgram is one of four in Alex’s Lemonade Stand Foundation-funded $18.5 million Crazy 8...
4 Report Package: "Drug the Undruggable" Technologies Bundle - Four Full Reports for the Price of Two
March 12, 2021 04:13 ET
|
Research and Markets
Dublin, March 12, 2021 (GLOBE NEWSWIRE) -- The "Report Package: "Drug the Undruggable" Technologies" report has been added to ResearchAndMarkets.com's offering. This report package includes four...